Global Market Direct’s pharmaceuticals report, “Norgine BV - Product Pipeline Review - 2013” provides data on the Norgine BV’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Norgine BV’s corporate website, SEC filings, investor presentations and featured press releases, both from Norgine BV and industry-specific third party sources, put together by Global Markets Direct’s team.
- Norgine BV - Brief Norgine BV overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Norgine BV human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Norgine BV with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Norgine BV’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Norgine BV’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Norgine BV in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Norgine BV’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Norgine BV. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Norgine BV and identify potential opportunities in those areas.
Table Of Contents
Norgine BV - Product Pipeline Review - 2013 Table of Contents 2 List of Tables 4 List of Figures 4 Norgine BV Snapshot 5 Norgine BV Overview 5 Key Information 5 Key Facts 5 Norgine BV - Research and Development Overview 6 Key Therapeutic Areas 6 Norgine BV - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Norgine BV - Pipeline Products Glance 10 Norgine BV - Late Stage Pipeline 10 Registration Filed Products/Combination Treatment Modalities 10 Phase III Products/Combination Treatment Modalities 11 Norgine BV Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Norgine BV - Early Stage Pipeline Products 13 Pre-Clinical Products/Combination Treatment Modalities 13 Norgine BV - Drug Profiles 14 cetilistat 14 Product Description 14 Mechanism of Action 14 RandD Progress 14 IBD Therapy 16 Product Description 16 Mechanism of Action 16 RandD Progress 16 methoxamine 17 Product Description 17 Mechanism of Action 17 RandD Progress 17 NPJ-5006 19 Product Description 19 Mechanism of Action 19 RandD Progress 19 NRL-994 20 Product Description 20 Mechanism of Action 20 RandD Progress 20 Norgine BV - Pipeline Analysis 21 Norgine BV - Pipeline Products by Therapeutic Class 21 Norgine BV - Pipeline Products by Route of Administration 22 Norgine BV - Pipeline Products By Mechanism of Action 23 Norgine BV - Recent Pipeline Updates 24 Norgine BV - Dormant Projects 25 Norgine BV - Discontinued Pipeline Products 26 Discontinued Pipeline Product Profiles 26 ulimorelin hydrochloride 26 Norgine BV - Company Statement 27 Norgine BV - Locations And Subsidiaries 28 Head Office 28 Appendix 29 Methodology 29 Coverage 29 Secondary Research 29 Primary Research 29 Expert Panel Validation 29 Contact Us 30 Disclaimer 30
List of Tables
Norgine BV, Key Information 5 Norgine BV, Key Facts 5 Norgine BV - Pipeline by Indication, 2013 7 Norgine BV - Pipeline by Stage of Development, 2013 8 Norgine BV - Monotherapy Products in Pipeline, 2013 9 Norgine BV - Filed, 2013 10 Norgine BV - Phase III, 2013 11 Norgine BV - Phase II, 2013 12 Norgine BV - Pre-Clinical, 2013 13 Norgine BV - Pipeline By Therapeutic Class, 2013 21 Norgine BV - Pipeline By Route of Administration, 2013 22 Norgine BV - Pipeline Products By Mechanism of Action, 2013 23 Norgine BV - Recent Pipeline Updates, 2013 24 Norgine BV - Dormant Developmental Projects,2013 25 Norgine BV - Discontinued Pipeline Products, 2013 26
List of Figures
Norgine BV - Pipeline by Indication, 2013 7 Norgine BV - Pipeline by Stage of Development, 2013 8 Norgine BV - Monotherapy Products in Pipeline, 2013 9 Norgine BV - Pipeline By Therapeutic Class, 2013 21 Norgine BV - Pipeline By Route of Administration, 2013 22 Norgine BV - Pipeline Products By Mechanism of Action, 2013 23